文献速递前列腺癌

68Ga-PSMA PET/CT用于mpMRI禁忌或阴性男性的前列腺癌初诊

68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study.
PubMed 文献 · J Urol · 2018-02-01

这项前瞻性观察研究纳入45例PSA持续升高和/或PHI可疑、直肠指检阴性且至少1次活检阴性、mpMRI不明确(PI-RADS v2≤2)或有mpMRI绝对/相对禁忌的男性,评估68Ga-PSMA PET/CT对前列腺癌初诊的价值。25例(55.5%)PET阳性者接受软件辅助融合活检;Gleason 7病变的摄取值显著高于Gleason 6或良性病变(p<0.001)。ROC分析显示SUVmax 5.4和SUVmax/背景比值2鉴别临床显著前列腺癌(Gleason≥7)的总敏感度均为100%,特异度分别为76%和88%。

要点

  • 68Ga-PSMA PET/CT可用于mpMRI禁忌或阴性、既往活检阴性但PSA持续升高男性的前列腺癌初诊。
  • Gleason 7病变的SUVmax或SUVmax/背景比值显著高于Gleason 6或良性病变(p<0.001)。
  • SUVmax 5.4和SUVmax/背景比值2鉴别Gleason≥7病变的总敏感度均为100%,特异度分别为76%和88%。

核心结论

  • 研究结果支持在特定亚组男性中使用68Ga-PSMA PET/CT进行前列腺癌初诊。

研究设计与样本

  • 前瞻性观察研究,纳入45例PSA持续升高和/或PHI可疑、直肠指检阴性且至少1次活检阴性、mpMRI不明确(PI-RADS v2≤2)或有mpMRI绝对/相对禁忌的男性,中位年龄64岁,2017年1月至8月转诊行68Ga-PSMA PET/CT。

主要发现

  • 25例(55.5%)PET阳性者接受软件辅助融合活检;感兴趣区中位SUVmax为5.34(范围2.25–30.41),中位SUVmax/背景比值为1.99(范围1.06–14.42)。
  • Gleason 7病变的SUVmax或SUVmax/背景比值显著高于Gleason 6或良性病变(p<0.001)。
  • ROC分析中SUVmax 5.4和SUVmax/背景比值2鉴别临床显著前列腺癌(Gleason≥7)的总敏感度均为100%,特异度分别为76%和88%。

关键数值与推荐

  • 临床显著前列腺癌定义为Gleason评分≥7。
  • SUVmax 5.4和SUVmax/背景比值2为ROC分析确定的鉴别Gleason≥7病变的最佳截断值,总敏感度均为100%,特异度分别为76%和88%。

临床怎么用

  • 对mpMRI禁忌或阴性、既往活检阴性但PSA持续升高和/或PHI可疑的男性,可考虑68Ga-PSMA PET/CT辅助初诊。
  • PET阳性者可针对感兴趣区行软件辅助融合活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography may represent the most promising imaging modality to identify and risk stratify prostate cancer in patients with contraindications to or negative multiparametric magnetic resonance imaging. MATERIALS AND METHODS: In this prospective observational study we analyzed 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography in a select group of patients with persistently elevated prostate specific antigen and/or Prostate Health Index suspicious for prostate cancer, negative digital rectal examination and at least 1 negative biopsy. The cohort comprised men with equivocal multiparametric magnetic resonance imaging (Prostate Imaging-Reporting and Data System, version 2 score of 2 or less), or an absolute or relative contraindication to multiparametric magnetic resonance imaging. Sensitivity, specificity and CIs were calculated compared to histopathology findings. ROC analysis was applied to determine the optimal cutoff values of 68Ga labeled prostate specific membrane antigen uptake to identify clinically significant prostate cancer (Gleason score 7 or greater). RESULTS: A total of 45 patients with a median age of 64 years were referred for 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography between January and August 2017. The 25 patients (55.5%) considered to have positive positron emission tomography results underwent software assisted fusion biopsy. We determined the uptake values of regions of interest, including a median maximum standardized uptake value of 5.34 (range 2.25 to 30.41) and a maximum-to-background standardized uptake value ratio of 1.99 (range 1.06 to 14.42). Mean and median uptake values on 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography (ie the maximum standardized uptake value or the maximum-to-background standardized uptake value ratio) were significantly higher for Gleason score 7 lesions than for Gleason score 6 or benign lesions (p <0.001). On ROC analysis a maximum standardized uptake value of 5.4 and a maximum-to-background standardized uptake value ratio of 2 discriminated clinically relevant prostate cancer with 100% overall sensitivity in each case, and 76% and 88% specificity, respectively. CONCLUSIONS: Our findings support the use of 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography for primary detection of prostate cancer in a specific subset of men.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lopci E, Saita A, Lazzeri M, et al. 68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study. J Urol. 2018. PMID: 29409824. doi:10.1016/j.juro.2018.01.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。